Staying in the back seat to Keytruda, Bristol Myers reports another pivotal setback in urothelial cancer
Just a few weeks after Bristol Myers Squibb and Nektar put the kibosh to their combo study of Opdivo and bempeg for metastatic urothelial cancer, one of the last big flameouts that convinced the pharma giant to squash their multibillion-dollar alliance, Bristol Myers is back with more bad news for the field.
Bumping into fresh trouble trying to move into a bigger position in frontline therapy, Bristol Myers reported that their Opdivo/Yervoy combo flopped in a Phase III study of first-line therapy for previously untreated patients with the most common form of bladder cancer. We don’t know the hard numbers yet, but the study — Checkmate-901 — failed to hit on overall survival.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.